Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eribulin mesylate + cetuximab
- Development stage
- Phase 2
- Lead developer
- Howard Safran
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Eribulin mesylate + cetuximab is a combination therapy investigated for the treatment of advanced malignancies, specifically head and neck squamous cell carcinoma (HNSCC) and colorectal cancer. Eribulin mesylate is a synthetic analog of halichondrin B, a small molecule that acts as a non-taxane microtubule dynamics inhibitor. It binds to the plus ends of microtubules, inhibiting the growth phase without affecting the shortening phase, which leads to irreversible mitotic blockade and apoptosis. Cetuximab is a recombinant human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the epidermal growth factor receptor (EGFR). By binding to EGFR, cetuximab inhibits the activation of the receptor and subsequent downstream signaling pathways, such as MAPK and PI3K/Akt, which are involved in cell proliferation, survival, and angiogenesis. The combination was evaluated in a Phase 1/2 study (NCT01266070) led by Dr. Howard Safran to determine safety and efficacy in patients who had progressed on prior therapies.
- Other names
- Eribulin and CetuximabEribulin mesylate and Cetuximab
02
Targets
EGFR (Epidermal growth factor receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on eribulin mesylate + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eribulin mesylate + cetuximab.